A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

• Status: RECRUITING
• Trial end date: 2033-06-30

Summary

This phase II trial tests the how well a precision medicine approach (serial measurements of molecular and architectural response to therapy \[SMMART\])-adaptive clinical treatment \[ACT\]) works in treating patients with sarcoma, prostate, breast, ovarian or pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). SMMART testing uses genetic and protein tests to learn how cancer changes and to understand what drugs may work against a person's cancer or why drugs stop working. These test results are reviewed by a group of physicians and scientists during a SMMART tumor board who then recommend precision therapy.

• Phase: PHASE2

Details

• Lead Sponsor: OHSU Knight Cancer Institute
• Collaborators: AstraZeneca; Eli Lilly and Company; Oregon Health and Science University
• Treatments: abemaciclib; Biopsy; Carboplatin; Doxorubicin; exemestane; Fulvestrant; Gefitinib; Gemcitabine; Letrozole; liposomal doxorubicin; olaparib; osimertinib; Paclitaxel; Pemetrexed; Tamoxifen; Taxes; Temozolomide